Suppr超能文献

运动时的固有心率与β-肾上腺素能受体阻滞作用的测定。

Intrinsic heart rate on exercise and the measurement of beta-adrenoceptor blockade.

机构信息

Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Belfast, Northern Ireland.

出版信息

Br J Clin Pharmacol. 1976 Dec;3(6):991-9. doi: 10.1111/j.1365-2125.1976.tb00348.x.

Abstract

Methods of expressing the effects of beta-adrenoceptor blocking drugs on exercise heart rate have been evaluated using a standardised exercise test. In six normal subjects given atropine (0.04 mg/kg) on two separate occasions, the mean +/- s.e. mean exercise heart rate rose by 10.3 +/- 1.8 beats/min and by 11.0 +/- 1.6 beats/min respectively. This increase was designated the 'vagal effect and was not significantly different in the two studies. After atropinsation, propranolol (0.2 mg/kg) reduced mean +/- s.e. mean exercise heart rate by 45.3 +/- 2.6 beats/min and 0.4 mg/kg by 50.8 +/- 4.5 beats/min. This mean sympathetic blockade was not altered significantly by increasing the dose of propranolol but, in four of the six subjects, the larger dose produced an increased effect of 4, 6, 12 and 16 beats/min, suggesting that maximum sympathetic blockade may not have been produced by 0.2 mg/kg. Knowledge of the vagal effect in each subject with standardised exercise enabled prediction to be made of the exercise heart rate after propranolol (0.4 mg/kg) without previous atropinisation. Propranolol (0.4 mg/kg) was then given intravenously to each subject and the actual exercise heart rate measured. There was no significant difference between the predicted and observed exercise heart rates. Propranolol (0.6 mg/kg) without atropine was then given to the four subjects who had shown increased effect with (0.4 mg/kg) and the sympathetic blockade was measured. In one subject, a further increase in sympathetic blockade of 10 beats/min was found. The intrinsic heart rate at rest and on exercise was measured for propranolol (0.2 and 0.4 mg/kg) and, for propranolol (0.6 mg/kg), the intrinsic heart rate on exercise was calculated. At rest, although no significant difference was found between the two dose levels, three subjects did not appear to have maximum autonomic blockade at 0.2 mg/kg. Similarly, several subjects had lower intrinsic heart rates on exercise after 0.4 or 0.6 mg/kg than after 0.2 mg/kg. The intrinsic heart rate on exercise was significantly greater than that obtained at rest. Using the maximum sympathetic blockade obtained in each subject as the sympathetic component of exercise, the effects of increasing oral doses of practolol on exercise heart were measured as percentage blockade of sympathetic effect and this was compared with other conventional methods of measuring beta-adrenoceptor blockade. It was found that percentage blockade of sympathetic effect correlated most closely with both percentage and absolute reduction of exercise heart rate. Correlations with exercise heart rate after drug and percentage inhibition of tachycardia, whilst also significant, did not appear as good. When the effects of practolol were expressed in terms of the potential blockade, a plateau occurred between 70 and 80% of 'maximum' sympathetic blockade. The failure to achieve higher levels with practolol may be the result of its partial agonist or intrinsic sympathomimetic activity.

摘要

方法表达的影响β-肾上腺素受体阻滞剂对运动心率的影响已经使用了一个标准化的运动试验进行评估。在 6 个正常的研究对象中,在两次不同的时间给予阿托品(0.04 毫克/千克),平均 +/- s.e.mean 运动心率分别升高了 10.3 +/- 1.8 次/分钟和 11.0 +/- 1.6 次/分钟。这种增加被称为“迷走神经效应”,在两次研究中没有显著差异。在阿托品化后,普萘洛尔(0.2 毫克/千克)降低平均 +/- s.e.mean 运动心率为 45.3 +/- 2.6 次/分钟和 0.4 毫克/千克 50.8 +/- 4.5 次/分钟。这种平均交感神经阻断作用没有随着普萘洛尔剂量的增加而显著改变,但在 6 个研究对象中的 4 个中,较大剂量产生了 4、6、12 和 16 次/分钟的增加作用,这表明 0.2 毫克/千克可能没有产生最大的交感神经阻断作用。在每个研究对象中,通过标准化运动获得的迷走神经效应的知识,使我们能够在没有先前阿托品化的情况下预测普萘洛尔(0.4 毫克/千克)后的运动心率。然后给每个研究对象静脉注射普萘洛尔(0.4 毫克/千克),并测量实际的运动心率。预测的和观察到的运动心率之间没有显著差异。然后,给已经显示出与(0.4 毫克/千克)增加效果的 4 个研究对象给予没有阿托品的普萘洛尔(0.6 毫克/千克),并测量了交感神经阻断作用。在一个研究对象中,发现进一步增加了 10 次/分钟的交感神经阻断作用。普萘洛尔(0.2 和 0.4 毫克/千克)测量了静息和运动时的固有心率,对于普萘洛尔(0.6 毫克/千克),计算了运动时的固有心率。在休息时,虽然在两个剂量水平之间没有发现显著差异,但有 3 个研究对象在 0.2 毫克/千克时似乎没有达到最大自主神经阻断作用。同样,一些研究对象在服用 0.4 或 0.6 毫克/千克普萘洛尔后,运动时的固有心率比服用 0.2 毫克/千克时低。运动时的固有心率明显大于休息时的固有心率。使用每个研究对象中获得的最大交感神经阻断作用作为运动的交感神经成分,测量了递增口服剂量的普拉洛尔对运动心率的影响,作为交感神经阻断作用的百分比,并将其与其他测量β-肾上腺素受体阻断作用的常规方法进行了比较。发现,与运动心率的百分比和绝对减少相比,交感神经阻断作用的百分比与运动心率的相关性最密切。与药物和心动过速抑制的百分比之间的相关性虽然也很显著,但似乎不如上述两种方法好。当普拉洛尔的作用以潜在的阻断作用表示时,在 70%至 80%的“最大”交感神经阻断作用之间出现了一个平台。普拉洛尔未能达到更高水平可能是由于其部分激动剂或内在拟交感神经活性。

相似文献

引用本文的文献

4
Mechanisms of the haematological changes induced by hyperventilation.过度通气引起血液学变化的机制。
Eur J Appl Physiol Occup Physiol. 1988;58(3):233-8. doi: 10.1007/BF00417255.
7
Intrinsic sympathomimetic activity of penbutolol.喷布洛尔的内在拟交感活性。
Eur J Clin Pharmacol. 1979;16(6):381-6. doi: 10.1007/BF00568197.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验